Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Harrow, Inc. - Common Stock (NQ:HROW)

30.15 +0.56 (+1.89%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Harrow, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Melt Pharmaceuticals Announces MELT-210 Top-Line Results of Phase 1 Pharmacokinetics (PK) Study for Procedural Sedation
From Melt Pharmaceuticals, Inc.
Via Business Wire
Harrow Health to Participate in B. Riley Securities’ Annual Neuro & Ophthalmology Investor Conference
From Harrow Health, Inc.
Via Business Wire
Harrow Health to Announce First Quarter 2022 Financial Results on May 5, 2022
From Harrow Health, Inc.
Via Business Wire
Earnings Scheduled For March 10, 2022
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares... 
Via Benzinga
Earnings Scheduled For August 10, 2021
Companies Reporting Before The Bell • Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its second quarter. • Fulcrum Therapeutics (NASDAQ:... 
Via Benzinga
Harrow Health Announces Appointments to Its Board of Directors
From Harrow Health, Inc.
Via Business Wire
Harrow Health to Announce Fourth Quarter and Year-End 2021 Financial Results on March 10, 2022
From Harrow Health, Inc.
Via Business Wire
Harrow Health Announces FDA Acceptance of New Drug Application for AMP-100
From Harrow Health, Inc.
Via Business Wire
Harrow Health to Present at Aegis Virtual Conference
From Harrow Health, Inc.
Via Business Wire
Two Insider Moonshots Rising on Sudden Buying
Biotech insiders are among the most important investors to pay close attention to. Here are two that show good signs for the future. 
Via InvestorPlace
Harrow Health Publishes Corporate Transparency Report
From Harrow Health, Inc.
Via Business Wire
Harrow Health to Participate in H.C. Wainwright BioConnect Conference
From Harrow Health, Inc.
Via Business Wire
Melt Pharmaceuticals Submits INDs for MELT‑210 and MELT-400 to FDA
From Melt Pharmaceuticals, Inc.
Via Business Wire
Harrow Health Acquires U.S. Commercial Rights to Four Branded Eye Drops
From Harrow Health, Inc.
Via Business Wire
Harrow Health Added to the Nasdaq Biotechnology Index
From Harrow Health, Inc.
Via Business Wire
The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Harrow Health Announces Third Quarter 2021 Financial Results
From Harrow Health, Inc.
Via Business Wire
Harrow Health to Announce Third Quarter 2021 Financial Results on November 9, 2021
From Harrow Health, Inc.
Via Business Wire
Harrow Health Provides $13.5 Million Senior Secured Loan to Melt Pharmaceuticals
From Harrow Health, Inc.
Via Business Wire
Harrow Health Acquires Japan-Approved Ophthalmic Injection For Undisclosed Sum
For an undisclosed amount, Harrow Health Inc (NASDAQ: HROW) has agreed to acquire MAQ-100 U.S. and Canadian commercial rights from Wakamoto... 
Via Benzinga
Harrow Health Acquires Ophthalmic Surgical Drug Candidate From Wakamoto Pharmaceutical Co., Ltd.
From Harrow Health, Inc.
Via Business Wire
Harrow Health to Participate in Two Upcoming Virtual Investor Conferences
From Harrow Health, Inc.
Via Business Wire
Harrow Health: Q2 Earnings Insights
Shares of Harrow Health (NASDAQ:HROW) were flat after the company reported Q2 results. Quarterly Results Earnings per share decreased 1000.00% year over year to ($0.11),... 
Via Benzinga
Harrow Health Announces Second Quarter 2021 Financial Results
From Harrow Health, Inc.
Via Business Wire
Harrow Health Acquires Patented Ophthalmic Surgical Drug Candidate from Sintetica
From Harrow Health, Inc.
Via Business Wire
NovaBay Pharmaceuticals Partners with Harrow Health’s ImprimisRx® to Promote Prescription Avenova
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Celldex Therapeutics (NASDAQ:CLDX) stock rose 41.93% to $46.0 during Monday's pre-market session. The company's market cap stands at $1.8 billion. 180 Life... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 2, 2021
Upgrades According to Deutsche Bank, the prior rating for Encompass Health Corp (NYSE: 
Via Benzinga
Harrow Health: Return On Capital Employed Insights
Harrow Health (NASDAQ:HROW) posted a 7.77% decrease in earnings from Q4. Sales, however, increased by 5.81% over the previous quarter to $15.44 million. Despite the increase in... 
Via Benzinga
60 Biggest Movers From Yesterday
Gainers Big Rock Partners Acquisition Corp. (NASDAQ: BRPA) shares jumped 88% to settle at $36.08 on Thursday. Urban One, Inc. (NASDAQ: UONE) gained 59.1% to close at $9.56. Urban... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.